Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for celgene
123.38
+0.16 (0.13%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 122.95 - 124.13
52 week 94.42 - 127.64
Open 123.72
Vol / Avg. 2.85M/4.02M
Mkt cap 96.11B
P/E 49.62
Div/yield     -
EPS 2.49
Shares 777.97M
Beta 1.78
Inst. own 80%
Jan 26, 2017
Q4 2016 Celgene Corp Earnings Release (Estimated)
Jan 9, 2017
Celgene Corp at JPMorgan Healthcare Conference - Q&A Session
Jan 9, 2017
Celgene Corp at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 14.39% 17.80%
Operating margin 21.08% 25.02%
EBITD margin - 33.76%
Return on average assets 6.27% 7.26%
Return on average equity 28.09% 31.94%
Employees 7,132 -
CDP Score - 97 C

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jacqualyn A. Fouse Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Mark J. Alles Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Chairman - Celgene Research
Age: 62
Bio & Compensation  - Reuters
Scott A. Smith President, Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Rupert Vessey President - Research and Early Development
Bio & Compensation  - Reuters
Gerald F. Masoudi Executive Vice President, General Counsel and Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 57
Bio & Compensation  - Reuters